Takeda And Hutchmed Announce Fda New Drug Application (Nda) For Fruquintinib
Takeda And Hutchmed Announced That The U.S. Food And Drug Administration (Fda) Has Granted Priority Review Of The New Drug Application (Nda) For Fruquintinib, A Highly Selective And Potent Inhibitor Of Vascular Endothelial Growth Factor Receptors (Vegfr) -1, -2 And -3 For The Treatment Of Adult Patients With Previously Treated Metastatic Colourectal Cancer (Crc).Fruquintinib Is A Highly Selective And Potent Oral Inhibitor Of Vegfr -1, -2 And -3. Vegfr Inhibitors Play A Pivotal Role In Blocking Tumour Angiogenesis. Fruquintinib Is Designed To Improve Kinase Selectivity With The Intention Of Minimising Off-Target Toxicities, Improving Tolerability And Providing More Consistent Target Coverage.There Are Significant Needs For Patients With This Disease In The U.S., And Fruquintinib Has The Potential To Address These Needs Regardless Of Patients
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!